KUBESPHERE
27.5.2021 09:50:06 CEST | Business Wire | Press release
KubeSphere Community announced the general availability of KubeSphere v3.1.0. KubeSphere, as an app-centric distributed operating system running on top of Kubernetes, has further expanded its portfolio to deliver more robust experiences for users across the globe, enabling DevOps teams to run Kubernetes workloads where and when they want with ease and security.
“KubeSphere has emerged as one of the most popular Kubernetes platforms ,” said Ray Zhou, Head of the KubeSphere project. “The release of KubeSphere 3.1 marks an important milestone as we further empower enterprises to gain first-mover advantages especially in edge computing.”
Taking Kubernetes From Hybrid Multi-Cloud to Edge
KubeSphere v3.1.0 provides an enabling environment for users as they can deploy production workloads not just across clouds but also at the edge . Besides, the new Metering and Billing function helps IT administrators better understand infrastructure operating costs. Existing features of multi-cluster management , multi-tenant management, observability, DevOps, application lifecycle management , and microservices governance have also been enhanced to ensure better user experiences across clusters and clouds .
Major updates include:
- Metering and billing to track infrastructure cost
- Edge node management for orchestrating apps and edge devices
- Lightweight Kubernetes multi-cloud and multi-cluster management
- Unified Kubernetes monitoring in one dashboard
- Easier Kubernetes installation
- Enhanced security with authentication and multi-tenancy
A full list of new features can be found in Release Note 3.1.0 . For a detailed introduction and interpretation, check out the latest KubeSphere 3.1.0 announcement
Commitment to Open-Source and Community
KubeSphere is making great strides on its international journey with over 100,000 downloads across 90 countries and regions to date. The KubeSphere console currently supports four official languages - English, Simplified Chinese, Traditional Chinese and Spanish.
“When you take a step back and reflect on how far KubeSphere has come, it is not surprising to find that it has become one of the most widely used container platforms not just in our country, but also around the world,” Ray added. “Our contributors from all corners of the world have shown us what open source is all about. And this is exactly what has been driving us to push the limits of what’s possible with Kubernetes.”
KubeSphere v3.1.0 remains committed to fully open source with an ever-expanding ecosystem, also helps developers to deploy code with several clicks on the friendly console, and brings integrated observability and powerful Kubernetes DevOps strategies for the Ops team.
About KubeSphere
KubeSphere is an open-source container platform based on Kubernetes. It provides full-stack IT automated operation and streamlined DevOps workflows. KubeSphere offers wizard web UI and enterprise-grade features for operation and maintenance, including multi-cloud and multi-cluster management , DevOps (CI/CD ), application lifecycle management , service mesh , multi-tenant , observability ,storage and network , and GPU support .
For more information, visit website https://kubesphere.io , GitHub https://github.com/kubesphere/kubesphere and follow @KubeSphere on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005328/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom